IP Library Granted Patent US 7,381,708
Granted Patent B2
US 7,381,708 · App. 10/383,614 · Granted Jun 3, 2008

Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye

Assignee: Sensco Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,708
App. No.
10/383,614
Granted
Jun 3, 2008
Kind
B2
Abstract

The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIF5A1.

Claims (7)

1. A method for inhibiting expression of human eIF5A1 set forth in SEQ ID NO: 47 in retinal ganglion cells, the method comprising administering to the retinal ganglion cells an antisense oligonucleotide targeted against the human eIF5A1, wherein the antisense oligonucleotide is selected from the group consisting of SEQ ID NOs: 41, 42 or 43, and wherein the antisense oligonucleotide is homologous to a polynucleotide encoding human eIF-5A1 set forth in SEQ ID NO: 45, wherein the antisense oligonucleotide inhibits expression of eIF5A1 in the cells.

2. The method of claim 1 wherein the antisense oligonucleotide is SEQ ID NO:42.

3. A method of inhibiting expression of human eIF5A1 set forth in SEQ ID NO: 47 in lamina cribosa cells, the method comprising administering to the lamina cribosa cells an antisense oligonucleotide targeted against human eIF5A1, wherein the antisense oligonucleotide is selected from the group consisting of SEQ ID NOs: 41, 42 or 43, and wherein the antisense oligonucleotide is homologous to a polynucleotide encoding human eIF-5A1 set forth in SEQ ID NO: 45 wherein the antisense oligonucleotide inhibits expression of eIF5A1 in the cells.

4. The method of claim 3 wherein the antisense oligonucleotide is SEQ ID NO:42.

5. A method of inhibiting expression of human eIF5A1 set forth in SEQ ID NO: 47 in astrocyte cells, the method comprising administering to the astrocyte cells an antisense oligonucleotide targeted against human eIF5A1, wherein the antisense oligonucleotide is selected from the group consisting of SEQ ID NOs: 41, 42 or 43, and wherein the antisense oligonucleotide is homologous to a polynucleotide encoding human eIF-5A1 set forth in SEQ ID NO: 45 wherein the antisense oligonucleotide inhibits expression of apoptosis-specific eIF5A1 in the cells.

6. The method of claim 5 wherein the antisense oligonucleotide comprises SEQ ID NO:42.

7. The method of claim 3 wherein the inhibiting expression of human eIF-5A1 reduces apoptosis in the lamina cribrosa cells.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Mar 25, 2010
From: YA GLOBAL INVESTMENTS, L.P.
To: SENESCO TECHNOLOGIES, INC.; SENESCO, INC.
Reel/Frame 024128/0676 →
SECURITY AGREEMENT Recorded Feb 5, 2008
From: SENESCO TECHNOLOGIES, INC.; SENESCO, INC.
To: YA GLOBAL INVESTMENTS, L.P.
Reel/Frame 020468/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIFTH LISTED ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 014386 FRAME 0616. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Nov 6, 2006
From: TAYLOR, CATHERINE; CLICHE, DOMINIC; SENCHYNA, DIANE MICHELLE; FLANAGAN, JOHN GERARD; THOMPSON, JOHN E.; HEIKKILA, ELIZABETH MARGARET
To: SENESCO TECHNOLOGIES, INC.
Reel/Frame 018485/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2003
From: TAYLOR, CATHERINE; CLICHE, DOMINIC; HEIKKILA, ELIZABETH MARGARET; SENCHYNA, DIANE MICHELLE; FLANNAGAN, JOHN GERARD; THOMPSON, JOHN E.
To: SENESCO TECHNOLOGIES, INC.
Reel/Frame 014386/0616 →
Continuity (6)
Continuation In Part 1027796900 · Oct 23, 2002
Continuation In Part 1020014800 · Jul 23, 2002
Continuation In Part 1014164700 · May 7, 2002
Continuation In Part 0990979600 · Jul 23, 2001
Provisional Application 6045167700 · May 5, 2003
Related Publication 20030225022A1 · Dec 4, 2003